MedTrace Logo

ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

NCT00397228 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2016-12-16

No results posted yet for this study

Summary

After a screening evaluation including baseline clinical laboratory testing, a physical and neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging. Subjects will undergo a second injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging within 2-6 weeks of the injection 1.

Conditions

  • Parkinson Disease

Interventions

DRUG

ALTROPANE®

ALTROPANE® SPECT imaging

Sponsors & Collaborators

  • Institute for Neurodegenerative Disorders

    collaborator OTHER

  • Molecular NeuroImaging

    lead OTHER

Principal Investigators

  • Danna Jennings, MD · Molecular NeuroImaging

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00397228 on ClinicalTrials.gov